Intrexon reported $23.72M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
Agenus USD 78.81M 16.47M Jun/2026
Alaunos Therapeutics USD 666K 304K Jun/2026
Amgen USD 34.36B 598M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.29B 382.19M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Intrexon USD 23.72M 45.04M Jun/2024
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
MannKind USD 240.48M 5.24M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
Veracyte USD 467.88M 106.9M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026